Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Older periods | Mar '25 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.01 | 15.70 | 19.24 | 12.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.94) | (1.83) | (1.57) | (0.79) | |
P/B ratio |
2.15 | 7.45 | 0.00 | 0.00 | |
Price to Tangible BV |
2.15 | 7.45 | 0.00 | 0.00 | |
EV/Sales |
(19.77) | (22.98) | (17.52) | (27.91) | |
EV/EBITDA |
0.28 | 0.42 | 0.30 | 0.36 | |
EV/Operating CF |
0.42 | 0.41 | 0.31 | 0.39 | |
EV/FCF |
0.40 | 0.41 | 0.31 | 0.38 | |
Quick Ratio |
2.77 | 2.67 | 2.33 | 1.67 | |
Current Ratio |
2.96 | 2.78 | 2.43 | 1.71 | |
Net Debt/EBITDA |
3.64 | 3.42 | 3.60 | 2.26 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
1.03 | 0.89 | 1.23 | 0.87 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | (0.96) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,664.48% | 2,792.35% | 16,188.00% | 62,542.86% | |
Selling, General and Administrative Expense of Revenue |
1,783.06% | 1,913.11% | 8,944.00% | 36,285.71% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
450.82% | 499.45% | 136.00% | 8,028.57% | |
Graham Net Nets |
(2.23) | (1.65) | (2.17) | (6.39) | |
Graham Number |
0.00 | 0.00 | 35.89 | 54.53 | |
Earnings Yield |
(957.28%) | (323.77%) | (358.19%) | (621.75%) | |
Free Cash Flow Yield |
(706.64%) | (357.39%) | (295.71%) | (604.17%) | |
Revenue per Share |
0.14 | 0.14 | 0.01 | 0.00 | |
Operating CF per Share |
(6.72) | (4.89) | (4.16) | (3.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.06) | |
Free Cash Flow per Share |
(6.72) | (4.89) | (4.16) | (3.97) | |
Cash per Share |
24.13 | 22.08 | 12.47 | 10.23 | |
Shareholders Equity per Share |
2.94 | 1.20 | (2.45) | (6.90) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.94 | 1.20 | (2.45) | (6.90) | |
Free Cash Flow |
(8.84) | (6.59) | (7.36) | (6.16) | |
Working Capital |
22.44 | 19.90 | 13.54 | 6.75 | |
Capital Expenditures |
— | 0.00 | 0.00 | (0.10) | |
Net Current Asset Value |
(18.54) | (19.89) | (25.02) | (30.55) | |
EV/EBIT |
0.29 | 0.43 | 0.30 | 0.36 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 13.71 | |
Net Profit Margin |
(4,670.49%) | (4,063.93%) | (23,936.00%) | (99,300.00%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.78 | 2.83 | 1.46 | 0.92 | |
Average Assets |
98.92 | 73.58 | 61.23 | 51.23 | |
Average Common Equity |
40.69 | 16.30 | 8.15 | 0.44 |
Columns are period end dates